<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01690091</url>
  </required_header>
  <id_info>
    <org_study_id>NT13034</org_study_id>
    <nct_id>NCT01690091</nct_id>
  </id_info>
  <brief_title>Cardioprotective and Metabolic Effects of Metformin in Patients With Heart Failure and Diabetes</brief_title>
  <acronym>CARMET</acronym>
  <official_title>Cardioprotective and Metabolic Effects of Metformin in Patients With Heart Failure and Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Clinical and Experimental Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute for Clinical and Experimental Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the effect of metformin on myocardial function, insulin&#xD;
      resistance and selected metabolic markers in patients with type 2 diabetes and heart failure&#xD;
      (HF+DM+) in a cross-over, randomized, placebo controlled trial.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      Metformin treatment in HF+DM+ group will lead to better myocardial function and load&#xD;
      tolerance in comparison to placebo. The degree of improvement will be linked to selected&#xD;
      metabolic parameters.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      40 patients with HF and DM without previous diabetes treatment will be randomized into 2&#xD;
      groups (A succession: MET-placebo, B succession: placebo-MET) - stratified randomization with&#xD;
      following parameters weighted: HF etiology (ischemic /non-ischemic), diabetes duration,&#xD;
      gender, BMI, age, NYHA, smoker/non-smoker). After 3 months the treatment will be switched.&#xD;
      All participants will undergo standardized selection of metabolic and cardiovascular tests&#xD;
      (hyperinsulinemic euglycemic clamp with indirect calorimetry, measurement of endothelial&#xD;
      function, echocardiography, spiroergometry, proton/phosphor MR spectroscopy, adipose tissue&#xD;
      biopsy, selected cytokines in plasma and adipose tissue at the beginning and the end of each&#xD;
      intervention period (3 times in total).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>at baseline and after 3 months</time_frame>
    <description>change of glucose disposal during clamp</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>energy expenditure</measure>
    <time_frame>at baseline and after 3 months</time_frame>
    <description>change of energy expenditure measured by indirect calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endothelial function</measure>
    <time_frame>at baseline and after 3 months</time_frame>
    <description>change in digital pulse amplitude tonometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart function</measure>
    <time_frame>at baseline and after 3 months</time_frame>
    <description>change measured by echocardiography and spiroergometry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening), duration: 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening), duration:3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformini hydrochloridum (Siofor 1000 tbl, Berlin)</intervention_name>
    <description>Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.&#xD;
Titration:&#xD;
500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening)</description>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>A10BA02 Metformin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.</description>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. chronic heart failure will be defined by the following criteria (all must be&#xD;
             included):&#xD;
&#xD;
               -  diagnosis of HF known for at least 6 months&#xD;
&#xD;
               -  medical history of hospitalization for cardiac decompensation with need for&#xD;
                  parenteral therapy for congestion - X-ray findings or swelling of lower&#xD;
                  extremities&#xD;
&#xD;
               -  stable drug therapy at least 1 month&#xD;
&#xD;
               -  treatment with diuretics (thiazide or furosemide)&#xD;
&#xD;
               -  LVEF below 50%&#xD;
&#xD;
          2. the presence of diabetes will be defined by:&#xD;
&#xD;
               -  diagnosis and treatment of type 2 diabetes in the medical history&#xD;
&#xD;
               -  screening blood sample:&#xD;
&#xD;
                    -  the value of HbA1c(according to IFCC)≥ 4.8% + fasting glucose ≥ 7.0 mmol / l&#xD;
                       in venous plasma or&#xD;
&#xD;
                    -  the value of HbA1c ≥ 4.8%(according to IFCC) + random blood glucose ≥ 11.1&#xD;
                       mmol/l in venous plasma&#xD;
&#xD;
                    -  or OGTT - blood glucose level at 120 min ≥ 11.1 mmol/l OGTT is indicated&#xD;
                       just in case of positivity of one of the criteria (fasting glucose + HbA1c&#xD;
                       or HbA1c + random blood glucose)&#xD;
&#xD;
               -  treatment of diabetes - by diet only&#xD;
&#xD;
               -  women and men aged 40-70 years&#xD;
&#xD;
               -  body mass index (kg/m2) in the range of 20-35&#xD;
&#xD;
               -  the range of HbA1c between 4-6,5% IFCC&#xD;
&#xD;
               -  signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. the planned cardiac intervention during the study that affect the function of the&#xD;
             heart (revascularization including PCI, heart surgery, implantation of pacemaker, RF&#xD;
             ablation; urgent candidate for OTS&#xD;
&#xD;
          2. metabolic disease, including: 1 type diabetes, decompensated thyreopathy (Note:&#xD;
             patients with hypothyroidism and stable substitution (the last 3 months) of normal TSH&#xD;
             levels may participate in the study&#xD;
&#xD;
          3. treatment with insulin or PAD one month before the recruitment(patients who were&#xD;
             temporarily treated with insulin during hospitalization may participate in the study)&#xD;
&#xD;
          4. pregnancy (positive β-HCG test), breast feeding, trying to become pregnant&#xD;
&#xD;
          5. clinically significant anemia with hemoglobin below 100 g/l&#xD;
&#xD;
          6. renal insufficiency with eGF below 0.7 ml/s&#xD;
&#xD;
          7. atrial fibrillation - present during screening test&#xD;
&#xD;
          8. the presence of other medical condition, which occurs during physical examination,&#xD;
             laboratory tests, ECG, including pulmonary, neurological or inflammatory disease,&#xD;
             which would be considered by the examiner to distort the consistency of data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terezie Pelikanova, Prof., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes Center, Institute of Clinical and Experimental Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes Center, Institute of Clinical and Experimental Medicine</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>March 12, 2012</study_first_submitted>
  <study_first_submitted_qc>September 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2012</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute for Clinical and Experimental Medicine</investigator_affiliation>
    <investigator_full_name>Prof. Terezie Pelikanova</investigator_full_name>
    <investigator_title>Prof.MUDr.Terezie Pelikanova DrSc.</investigator_title>
  </responsible_party>
  <keyword>chronic heart failure</keyword>
  <keyword>type 2 diabetes</keyword>
  <keyword>metformin</keyword>
  <keyword>insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

